Modified CV Regimen in Optic Pathway Glioma

Optic pathway glioma (OPG) can result in visual deterioration. Symptomatic patients often report deficits in visual acuity (VA), visual field, visual-evoked potentials (VEPs), strabismus, proptosis, disc swelling, and other visual/neurological problems. VA itself remains one of the most important outcome measures for OPG patients, with various studies showing strong ties of VA level to overall quality of life and well-being . Maintenance of favorable VA and vision outcomes is of paramount importance in the management of OPG. In terms of management of OPG, surgery and radiotherapy are used on

Trial Details

NCT ID
NCT05278715
Phase
PHASE2
Sponsor
Beijing Sanbo Brain Hospital
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Carboplatin
  • Vincristine
  • Recombinant human endostatin
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Age ≥ 3months and ≤21years;
  • Patients with optic pathway gliomas diagnosed by histopathology or characteristic brain MRI and clinical features;
  • Measurable lesions, surgical resection degree \< 95% or postoperative residual tumor ≥1.5cm\^2;
  • KPS score ≥50 (age \>12 years) or Lansky score ≥50 (age ≤12 years);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →